Kevin G. King
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kevin G. King has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Justin Lee
Department of Radiology, Keck School of Medicine of USC, Los Angeles, USA
2 shared publications - Phillip M. Cheng
Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA
2 shared publications - Shefali Chopra
Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, CA
2 shared publications Steven S. Raman
Department of Radiological Sciences, David Geffen School of Medicine, University of California at Los Angeles
2 shared publicationsAdam Morris
Charlotte, NC
1 shared publicationAkshay Shetty
Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles
1 shared publication
Latest Publications
- Open Access
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (15)
Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- 6 April 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (15)
Open AccessToward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test
Plasma cell-free DNA (cfDNA), originating from multiple organs, holds significant potential for noninvasive diagnostics and prognostics. Current cfDNA methylation assays primarily focus on single clinical indications by targeting specific genomic loci. In contrast, comprehensive profiling of cfDNA methylome can enable simultaneous detection of multiple diseases by capturing organ-specific methylation signatures, thereby offering a holistic view of health, when disease etiology is unclear or when conventional biochemical diagnostics are unavailable. However, deep sequencing required for sensitive detection of methylation abnormalities remains prohibitively expensive, limiting widespread clinical use. To overcome this barrier, we developed MethylScan , a highly cost-effective approach for cfDNA methylome sequencing. We demonstrated its broad clinical utility in a cohort of 1,061 individuals across diverse applications, including multicancer detection in general population, liver cancer surveillance in high-risk individuals, liver disease classification, identification of organ abnormalities, and race prediction from cfDNA. In multicancer detection (liver, lung, ovarian, and stomach cancers), MethylScan achieved an area under the receiver operating characteristic curve (AUROC) of 0.938 (95% CI: 0.920 to 0.954), with a sensitivity of 63.3% (95% CI: 58.9 to 67.9%) at 98.0% specificity for all cancer stages. For early-stage cancers, the AUROC was 0.916 (95% CI: 0.890 to 0.940), with 55.3% sensitivity (95% CI: 49.1 to 62.1%) at the same specificity. In liver cancer surveillance, MethylScan achieved an AUROC of 0.927 (95% CI: 0.889 to 0.959), with 79.6% sensitivity (95% CI: 70.6 to 87.8%) at 90.4% specificity. The assay also demonstrated strong performance in additional diagnostic tasks, supporting its potential as a versatile platform for comprehensive cfDNA-based health monitoring.
- Open Access
- 1 February 2024
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 222 (2)
Editorial Comment: Perfluorobutane Increases Sensitivity and Accuracy in Hepatocellular Carcinoma Diagnosis Compared With Purely Intravascular Contrast Agents
- 1 February 2024
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 222 (2)
Open AccessEditorial Comment: Perfluorobutane Increases Sensitivity and Accuracy in Hepatocellular Carcinoma Diagnosis Compared With Purely Intravascular Contrast Agents
- Open Access
- 17 February 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 48 (5) , 1831-1839
Correction: Perinephric myxoid pseudotumor of fat: a multimodality imaging case series
- 17 February 2023
- Published by Springer Nature in Abdominal Radiology
- Vol. 48 (5) , 1831-1839
Open AccessCorrection: Perinephric myxoid pseudotumor of fat: a multimodality imaging case series
- 1 January 2023
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 9, 8
Contrast-enhanced ultrasound for hepatocellular carcinoma detection and diagnosis in the context of nonalcoholic fatty liver disease
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
- 1 January 2023
- Published by OAE Publishing Inc. in Hepatoma Research
- Vol. 9, 8
Contrast-enhanced ultrasound for hepatocellular carcinoma detection and diagnosis in the context of nonalcoholic fatty liver disease
Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination and early diagnosis of hepatoma, complications of hepatoma, and their preventions and treatments, etc.
- 9 September 2022
- Published by Springer Nature in Abdominal Radiology
- Vol. 48 (5) , 1820-1830
Perinephric myxoid pseudotumor of fat: a multimodality imaging case series
Perinephric myxoid pseudotumor of fat (PMPF) is an unusual clinical entity with few prior imaging case reports. We report a multimodality imaging case series of PMPF, consisting of four cases seen in our department with both imaging studies and histopathologic confirmation. Three of the four patients had a history of advanced non-neoplastic renal disease. The perirenal masses in these cases varied in size and appearance. Some lesions resembled cysts or contained macroscopic fat. Enhancement was equivocal on CT, but prominent in one case on MRI and in another on contrast-enhanced ultrasound. Although not known to be malignant, PMPF may be confused for a cyst, liposarcoma, or hypovascular solid neoplasm on imaging. The dominant mass was resected in two cases because of concern for malignancy, while percutaneous CT-guided biopsy was performed in the other two. Mouse double minute 2 (MDM2) gene amplification by fluorescence in situ hybridization (FISH) was negative in all four cases, excluding well-differentiated liposarcoma. Radiologists should be familiar with PMPF to provide appropriate guidance on clinical management. Graphical abstract
- 9 September 2022
- Published by Springer Nature in Abdominal Radiology
- Vol. 48 (5) , 1820-1830
Perinephric myxoid pseudotumor of fat: a multimodality imaging case series
Perinephric myxoid pseudotumor of fat (PMPF) is an unusual clinical entity with few prior imaging case reports. We report a multimodality imaging case series of PMPF, consisting of four cases seen in our department with both imaging studies and histopathologic confirmation. Three of the four patients had a history of advanced non-neoplastic renal disease. The perirenal masses in these cases varied in size and appearance. Some lesions resembled cysts or contained macroscopic fat. Enhancement was equivocal on CT, but prominent in one case on MRI and in another on contrast-enhanced ultrasound. Although not known to be malignant, PMPF may be confused for a cyst, liposarcoma, or hypovascular solid neoplasm on imaging. The dominant mass was resected in two cases because of concern for malignancy, while percutaneous CT-guided biopsy was performed in the other two. Mouse double minute 2 (MDM2) gene amplification by fluorescence in situ hybridization (FISH) was negative in all four cases, excluding well-differentiated liposarcoma. Radiologists should be familiar with PMPF to provide appropriate guidance on clinical management. Graphical abstract
- 1 September 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 219 (3) , 444
Editorial Comment: Future Incorporation of Kupffer Cell Agents Into Contrast-Enhanced Ultrasound LI-RADS May Increase Sensitivity for HCC Without Compromising Specificity
This Editorial Comment discusses the following AJR article: Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
- 1 September 2022
- Published by American Roentgen Ray Society in American Journal of Roentgenology
- Vol. 219 (3) , 444
Editorial Comment: Future Incorporation of Kupffer Cell Agents Into Contrast-Enhanced Ultrasound LI-RADS May Increase Sensitivity for HCC Without Compromising Specificity
This Editorial Comment discusses the following AJR article: Contrast-Enhanced Ultrasound Using Perfluorobutane: Impact of Proposed Modified LI-RADS Criteria on Hepatocellular Carcinoma Detection.
- Open Access
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4S) , e1335-e1336
MP100-14 HIGH INTENSITY FOCUSED ULTRASOUND KIDNEY ABLATION: PRE-CLINICAL SAFETY AND EFFICACY EVALUATION IN A PORCINE MODEL USING A 15MM LAPAROSCOPIC PROBE
- 1 April 2017
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 197 (4S) , e1335-e1336
Open AccessMP100-14 HIGH INTENSITY FOCUSED ULTRASOUND KIDNEY ABLATION: PRE-CLINICAL SAFETY AND EFFICACY EVALUATION IN A PORCINE MODEL USING A 15MM LAPAROSCOPIC PROBE